Genetics & Epigenetics Library
Every article, presentation, spotlight, and news item we've tagged to Genetics & Epigenetics.
Showing 145–168 of 176
Building a ‘Swiss Army Knife’ longevity drug
LinkGevity is developing a small-molecule therapeutic targeting necrosis—uncontrolled cell death—as an upstream driver of multiple age-related diseases. By intervening at this central physiological node, the approach aims to address degenerative change across chronic conditions simultaneously rather than treating diseases individually.
International patent published for sirtuin 6 muscle therapy
Genflow Biosciences published a patent application for sirtuin 6 variants designed to prevent and treat muscle-mass loss, frailty, and sarcopenia through gene therapy. This approach targets a fundamental mechanism of age-related decline by restoring a protein variant associated with extended lifespan.
A Cluster of Three snoRNAs Including Jouvence Required in the Gut Determines Lifespan and Confers Neuroprotection Through Metabolic Parameters
A cluster of three small nucleolar RNAs in the gut epithelium regulates lipid and sterol metabolism, with direct effects on lifespan and neuroprotection in aging. Disruption of these snoRNAs causes metabolic dysregulation that leads to neurodegeneration, while restoration in gut cells alone is sufficient to reverse these effects.
Infinite Epigenetics acquires Tally Health
Infinite Epigenetics acquired Tally Health, combining epigenetic testing platforms, laboratory infrastructure, and personalized intervention products. The merger positions epigenetic age assessment as a diagnostic tool paired with targeted supplementation and lifestyle recommendations for consumers pursuing longevity optimization.
Gut Microbiome Testing Paired With Unproven Longevity Compounds
Decode Age, a Bengaluru-based sequencing laboratory and supplement company, combines gut microbiome testing with the sale of compounds including NMN, resveratrol, spermidine, and alpha-ketoglutarate, marketed as bioage interventions. The startup has grown to ₹11.9 crore in annual revenue with recent institutional funding, though human efficacy data for these compounds remains limited.
FOXM1 activation reverses endothelial aging in atherosclerosis
A platelet membrane-coated resveratrol nanoparticle system activates FOXM1 to restore mitochondrial function and reverse endothelial senescence in atherosclerosis models. The approach addresses both the bioavailability limitations of resveratrol and the cellular dysfunction underlying vascular pathology.
Imaging-derived biological age across multiple organs links to mortality and aging-related health outcomes
Imaging-derived biological age—a measure of structural aging across multiple organs—independently predicts mortality and age-related disease risk beyond chronological age. This multi-organ assessment reveals that heterogeneous aging patterns across tissues provide clinically actionable information for longevity planning and intervention timing.
Alzheon doses first subject in Phase 1 of ALZ-507
Alzheon has initiated Phase 1 trials of ALZ-507, an oral small molecule designed to inhibit neurotoxic amyloid oligomer formation and correct APOE4 dysfunction. The compound demonstrates favorable preclinical safety and pharmacokinetic profiles supporting once-daily dosing, with Phase 2 studies planned across Alzheimer's disease, Down syndrome-associated AD, and cerebral amyloid angiopathy.
Infinite Epigenetics acquires Tally Health
Infinite Epigenetics acquired Tally Health to integrate epigenetic testing with clinical infrastructure and consumer interventions, creating a closed-loop system that aims to move biological age measurement from research curiosity into actionable preventive healthcare. The consolidation represents an attempt to resolve the gap between epigenetic data capture and demonstrable clinical outcomes.
Laser-induced epigenetic reversal restores skin age markers
A non-ablative fractional laser treatment produced measurable shifts in skin epigenetic markers associated with aging, with 83.9% of age-related CpG sites showing DNA methylation changes consistent with biological reversal. Visible improvements in pigmentation and texture paralleled molecular changes over a six-month period, suggesting the intervention operates at both the genetic regulation and tissue-level domains.
Cell therapies achieve durable regeneration without immunosuppression
Sana Biotechnology is advancing multiple cell and gene therapy candidates toward clinical trials in 2026-2027, with SC451 expected to enter Phase 1/2 trials as early as 2026 and preclinical data demonstrating targeted cell delivery without chemotherapy depletion. The company's $160.5 million cash position and strategic partnerships position it to pursue regenerative approaches for conditions ranging from autoimmune disease to type 1 diabetes.
Basecamp Research’s new gene atlas could speed longevity R&D
Basecamp Research's Trillion Gene Atlas expands genetic reference data 100-fold across 100 million species to improve AI drug discovery models for aging. The underlying premise is that current AI systems underperform not due to model limitations but because they train on narrow, repetitive biological data insufficient for solving complex, multisystem conditions like aging.
Human cGAS Drives LINE‐1 Transcriptional Activation to Trigger MAVS‐Dependent Cellular Senescence
Human cGAS activates LINE-1 retrotransposon transcription through upregulation of CTCF and RUNX3, triggering cellular senescence via MAVS-dependent RNA sensing. This human-specific pathway reveals a mechanism linking genomic surveillance to accelerated cellular aging, with direct implications for understanding senescence in aging and age-related disease.
Dopamine neuron replacement for Parkinson's gains FDA regulatory acceleration
The FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to Aspen Neuroscience's sasineprocel, a personalized cell therapy that replaces dopamine-producing neurons lost to Parkinson's disease rather than masking symptoms with dopamine replacement. This regulatory milestone accelerates development pathways for a therapy addressing a core mechanism of neurodegeneration—cellular loss—rather than compensating for it.
SIRT6 Gene Therapy Gains Fast-Track Patent Review for Frailty
Genflow secured expedited US patent review for SIRT6 gene variants targeting age-related muscle loss and frailty. This represents a strategic intellectual property consolidation for a gene therapy platform designed to modulate aging-related decline in muscular function.
Region-specific transcriptional signatures of brain aging in the absence of neuropathology at the single-cell level
Single-cell transcriptional analysis reveals region-specific aging signatures in the brain that occur independently of classical neuropathology, suggesting aging involves coordinated transcriptional changes across distinct neural populations. This finding establishes a molecular basis for understanding how brain regions age differently and may identify intervention points before pathological hallmarks emerge.
Zfp462 Is a Key Mediator of Osteoblast Differentiation and Might Contribute to Age‐Related Bone Loss
Zfp462 is a transcriptional regulator essential for osteoblast differentiation and bone formation; aging reduces its expression through altered histone occupancy at its locus, providing a mechanistic explanation for age-related bone loss. Restoring Zfp462 activity or its associated transcriptional machinery represents a potential intervention pathway for senile osteoporosis.
FAM162A Is a Key Regulator of Mitochondrial Structure, Dynamics, and Bioenergetics, Driving Cellular Protection and Longevity
FAM162A, a mitochondrial cristae protein, regulates mitochondrial structure and energy production through interaction with OPA1, enhancing cellular stress resistance and extending lifespan in model organisms. This identifies a previously unrecognized mechanism linking mitochondrial dynamics to organismal longevity.
Formulation Specificity, Not Ingredient Alone, Predicts Epigenetic Age
In a cohort of 4,260 health-conscious individuals, delayed-release calcium-alpha-ketoglutarate combined with vitamins was associated with 1.8 years lower epigenetic age, while standard AKG and CoQ10 showed minimal or non-significant benefits. The findings suggest specificity in formulation matters more than ingredient alone, and future controlled trials are needed to establish causation.
Cholesterol Drainage Therapy Reverses Atherosclerosis and Liver Disease
Repair Biotechnologies has developed REP-0004, an mRNA therapy delivered via lipid nanoparticles to the liver, designed to reduce excess intracellular free cholesterol and trigger systemic cholesterol drainage. The drug has received orphan drug designation and aims to enter clinical trials by mid-2027, with preclinical data suggesting rapid regression of atherosclerotic plaque and reversal of metabolic liver disease.
Alzheon pushes oral Alzheimer’s pipeline forward
Alzheon has dosed the first healthy volunteers in a Phase 1 trial of ALZ-507, an oral Alzheimer's candidate designed to prevent amyloid clumping and correct APOE4 dysfunction. The drug represents a shift toward earlier intervention and simplified delivery in a disease where accessibility and tolerability have historically limited treatment adoption.
NK Cell Therapy Targets Immune Dysfunction in Neurodegeneration
NKGen Biotech is advancing Troculeucel, an autologous natural killer cell therapy, through Phase 2 trials for Alzheimer's disease with expansion into other neurodegenerative conditions. The approach targets immune system dysfunction in neurodegeneration, representing a distinct mechanistic pathway from conventional pharmacological interventions.
Brain cholesterol independence reshapes Alzheimer's risk strategy
Lipid-lowering therapies do not impair brain health or cognitive function through excessive LDL cholesterol reduction. The brain maintains independent cholesterol homeostasis and synthesizes its own cholesterol, rendering systemic LDL levels largely irrelevant to cerebral lipid availability or Alzheimer's disease risk.
Cell Response Algorithm Accelerates Longevity Research
Researchers at Altos Labs developed PRiMeFlow, a machine learning algorithm that predicts how cells respond to genetic and molecular interventions by working directly within gene expression space rather than compressing data into lower dimensions. This advance enables more accurate in silico modeling of cellular behavior, reducing the need for costly and time-consuming experimental validation before testing therapeutic candidates.